JOP20230102A1 - مثبط إنتجرين واستخداماته - Google Patents

مثبط إنتجرين واستخداماته

Info

Publication number
JOP20230102A1
JOP20230102A1 JOJO/P/2023/0102A JOP20230102A JOP20230102A1 JO P20230102 A1 JOP20230102 A1 JO P20230102A1 JO P20230102 A JOP20230102 A JO P20230102A JO P20230102 A1 JOP20230102 A1 JO P20230102A1
Authority
JO
Jordan
Prior art keywords
methods
integrin inhibitor
crystalline forms
integrin inhibitors
forms
Prior art date
Application number
JOJO/P/2023/0102A
Other languages
English (en)
Inventor
Jacob Cha
Gao Qi
Dalian Zhao
Katerina Leftheris
Jian Wang
Original Assignee
Pliant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliant Therapeutics Inc filed Critical Pliant Therapeutics Inc
Publication of JOP20230102A1 publication Critical patent/JOP20230102A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

يتعلق الاختراع الحالي بمثبطات أنتجرين وتركيباتها وطرق لاستخدامها. كما تم وصف الأشكال البلورية لأملاح المثبطات وطرق تحضير الأشكال البلورية. يتم توفير بيانات حيود الأشعة السينية في المسحوق، والتحليل الحراري الوزني، وبيانات قياس السعرات الحرارية بالمسح التفاضلي للأشكال البلورية. تعتبر مثبطات الإنتجرين مفيدة في أمور كثيرة منها معالجة أمراض التليف.--
JOJO/P/2023/0102A 2020-11-19 2023-05-08 مثبط إنتجرين واستخداماته JOP20230102A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063116042P 2020-11-19 2020-11-19
PCT/US2021/072510 WO2022109598A1 (en) 2020-11-19 2021-11-19 Integrin inhibitor and uses thereof

Publications (1)

Publication Number Publication Date
JOP20230102A1 true JOP20230102A1 (ar) 2023-05-08

Family

ID=81709878

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0102A JOP20230102A1 (ar) 2020-11-19 2023-05-08 مثبط إنتجرين واستخداماته

Country Status (19)

Country Link
US (2) US12018025B2 (ar)
EP (1) EP4247472A4 (ar)
JP (1) JP2023550428A (ar)
KR (1) KR20230121761A (ar)
CN (1) CN116710169A (ar)
AU (1) AU2021381516A1 (ar)
CA (1) CA3173755A1 (ar)
CL (1) CL2023001418A1 (ar)
CO (1) CO2023006522A2 (ar)
CR (1) CR20230262A (ar)
CU (1) CU20230026A7 (ar)
DO (1) DOP2023000101A (ar)
EC (1) ECSP23045278A (ar)
IL (1) IL302651A (ar)
JO (1) JOP20230102A1 (ar)
MX (1) MX2023005889A (ar)
PE (1) PE20240114A1 (ar)
TW (1) TW202235417A (ar)
WO (1) WO2022109598A1 (ar)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
CN114173803A (zh) 2019-04-08 2022-03-11 普利安特治疗公司 氨基酸化合物的剂型和方案
CN120091811A (zh) * 2022-07-09 2025-06-03 普利安特治疗公司 整合素抑制剂及其与其它药剂组合的用途
WO2024155965A2 (en) * 2023-01-21 2024-07-25 Pliant Therapeutics, Inc. Biomarkers for use in integrin inhibitor therapy
WO2025072206A1 (en) * 2023-09-25 2025-04-03 Pliant Therapeutics, Inc. Integrin inhibitors for treatment of primary sclerosing cholangitis
US20250197393A1 (en) 2023-12-14 2025-06-19 Pliant Therapeutics, Inc. Integrin inhibitor and uses thereof
WO2025217571A1 (en) * 2024-04-12 2025-10-16 Pliant Therapeutics, Inc. Fixed dose combinations of integrin inhibitor with ppar agonists

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210033067A (ko) * 2012-06-04 2021-03-25 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
WO2016145258A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
EP3509590A4 (en) 2016-09-07 2020-12-02 Pliant Therapeutics, Inc. N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
MX394210B (es) 2017-02-28 2025-03-04 Morphic Therapeutic Inc INHIBIDORES DE INTEGRINA AVß6.
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
FI3761980T3 (fi) * 2018-03-07 2024-02-21 Pliant Therapeutics Inc Aminohappoyhdisteitä ja käyttömenetelmiä
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
WO2020016704A1 (ja) * 2018-07-20 2020-01-23 株式会社半導体エネルギー研究所 撮像パネル、撮像装置
WO2020047207A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutics, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2020047239A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
WO2020139379A1 (en) * 2018-12-28 2020-07-02 LunaPBC Community data aggregation, completion, correction, and use
US11730144B2 (en) * 2019-02-15 2023-08-22 Clean Bite, Llc Oral hygiene appliance
CN114173803A (zh) * 2019-04-08 2022-03-11 普利安特治疗公司 氨基酸化合物的剂型和方案
WO2021097338A1 (en) 2019-11-15 2021-05-20 Pliant Therapeutics, Inc. Compositions and methods for activation of integrins
CN115989235A (zh) * 2020-05-07 2023-04-18 普利安特治疗公司 使用氨基酸化合物治疗呼吸系统疾病的方法
TWI843503B (zh) * 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
WO2022087224A1 (en) * 2020-10-21 2022-04-28 Cohbar, Inc. Method of treating fibrosis with a combination therapy
MX2023012794A (es) 2021-04-30 2023-12-15 Pliant Therapeutics Inc Regímenes de dosificación expandidos para inhibidores de integrina.
US20240350494A1 (en) 2021-09-03 2024-10-24 Pliant Therapeutics, Inc. Therapeutic modulation of integrins
TW202329973A (zh) 2021-10-14 2023-08-01 美商普萊恩醫療公司 整合素抑制劑及其與其他藥劑併用之用途
JP2025518533A (ja) 2022-05-18 2025-06-17 プライアント・セラピューティクス・インコーポレイテッド インテグリン阻害剤の安定化

Also Published As

Publication number Publication date
CA3173755A1 (en) 2022-05-27
AU2021381516A9 (en) 2024-10-24
DOP2023000101A (es) 2023-09-29
MX2023005889A (es) 2023-06-06
US20220177468A1 (en) 2022-06-09
CR20230262A (es) 2023-07-26
EP4247472A1 (en) 2023-09-27
EP4247472A4 (en) 2024-10-09
CL2023001418A1 (es) 2023-10-30
ECSP23045278A (es) 2023-07-31
CO2023006522A2 (es) 2023-06-09
KR20230121761A (ko) 2023-08-21
US12018025B2 (en) 2024-06-25
WO2022109598A1 (en) 2022-05-27
TW202235417A (zh) 2022-09-16
CU20230026A7 (es) 2024-01-10
JP2023550428A (ja) 2023-12-01
IL302651A (en) 2023-07-01
US20240391914A1 (en) 2024-11-28
AU2021381516A1 (en) 2023-06-22
PE20240114A1 (es) 2024-01-22
CN116710169A (zh) 2023-09-05

Similar Documents

Publication Publication Date Title
JOP20230102A1 (ar) مثبط إنتجرين واستخداماته
MX2020011294A (es) Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de cinasa dependientes de ciclina.
MX2021009276A (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidora sobre cdk2.
CR20200452A (es) Compuestos de aminoacidos y métodos de uso
MY198534A (en) Pyridopyrimdinone cdk2/4/6 inhibitors
PH12020552187A1 (en) Pcsk9 antagonist compounds
MX2022007130A (es) Derivados de piperazina sustituidos utiles como activadores de celulas t.
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
ECSP109910A (es) Derivados de n-(arilamino) sulfonamidas que incluyen polimorfos como inhibidores de mek así como composiciones, métodos de uso y de preparación de los mismos
IL296199B2 (en) Salt form of a human hi stone methyltransf erase ezh2 inhibitor
CY1122974T1 (el) Κρυσταλλοι ενωσης 2-acylaminothiazole
CY1119076T1 (el) Αλατα πιπεραζινης ως ανταγωνιστες των d3/d2
CY1112019T1 (el) Αγωνιστες υποδοχεων νιασινης, συνθεσεις που περιεχουν τετοιες ενωσεις και μεθοδοι θεραπειας
JOP20250025A1 (ar) صور بلورية وأملاح من ناهض مستقبل مسكاريني
CY1118146T1 (el) Σταθερες σε αποθηκευση φαρμακοτεχνικες μορφες σουλφοναμιδιων
SI2185155T1 (en) Pharmaceutical compositions containing dopamine receptor ligands and treatment procedures using ligands of dopamine receptors
FI20115234A0 (fi) Uusia pyridatsinoni- ja pyridoniyhdisteitä
BR112017017275A2 (pt) composto, composição farmacêutica, método para o tratamento e uso do composto
MY206797A (en) Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain
MY198008A (en) Crystal of benzofuran derivative free base and preparation method
JOP20210072A1 (ar) ملح جديد لمثبط bcl-2، صورة بلورية ذات صلة، طريقة تحضيره وتركيبات صيدلية تحتوي عليه
MX2024005429A (es) Inhibidores de las fosfatidilinositol 3-cinasas-alfa (pi3k-alfa) y metodos para su produccion y uso.
PL441331A1 (pl) Ulepszenia inhibitorów nitryfikacji i ulepszenia dotyczące inhibitorów nitryfikacji
JOP20240171A1 (ar) مركبات يوراسيل بها استبدال بـ n3 على هيئة مثبطات trpa1
CL2007002533A1 (es) Sal de {1-metil-5-[2-(5-trifluorometil-1h-imidazol-2-il)-piridin-4-iloxi]-1h-benzoimidazol-2-il}-(4-trifluorometil-fenil)amina; metodo de preparacion; composicion farmaceutica que la comprende; metodo para preparar la composicion; y uso para tratar e